David E.Activist Investing ... Net Worth

The estimated Net Worth of David E.Activist Investing ... is at least $23.7 Million dollars as of 24 January 2023. David Investing owns over 57,500 units of Titan Pharmaceuticals, (de) stock worth over $19,079,518 and over the last 2 years David sold TTNP stock worth over $4,610,001.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

David Investing TTNP stock SEC Form 4 insiders trading

David has made over 3 trades of the Titan Pharmaceuticals, (de) stock since 2022, according to the Form 4 filled with the SEC. Most recently David sold 3,747,968 units of TTNP stock worth $4,610,001 on 21 June 2023.

The largest trade David's ever made was selling 3,747,968 units of Titan Pharmaceuticals, (de) stock on 21 June 2023 worth over $4,610,001. On average, David trades about 2,010,553 units every 117 days since 2022. As of 24 January 2023 David still owns at least 3,388,902 units of Titan Pharmaceuticals, (de) stock.

You can see the complete history of David Investing stock trades at the bottom of the page.

Insiders trading at Titan Pharmaceuticals, (de)

Over the last 9 years, insiders at Titan Pharmaceuticals, (de) have traded over $4,610,001 worth of Titan Pharmaceuticals, (de) stock and bought 3,252,657 units worth $2,558,794 . The most active insiders traders include David E.Activist Investing ..., James R Mcnab und Marc Rubin. On average, Titan Pharmaceuticals, (de) executives and independent directors trade stock every 204 days with the average trade being worth of $2,815,253. The most recent stock trade was executed by David E.Activist Investing ... on 21 June 2023, trading 3,747,968 units of TTNP stock currently worth $4,610,001.

What does Titan Pharmaceuticals, (de) do?

titan pharmaceuticals inc. is developing proprietary therapeutics primarily for the treatment of serious medical disorders. the company's lead product is probuphine®, the first and only commercialized treatment of opioid dependence to provide continuous, around-the-clock blood levels of buprenorphine for six months following a single procedure. it was approved by the u.s. food and drug administration in may 2016 and is being commercialized in the u.s. by partner braeburn pharmaceuticals. probuphine employs titan's proprietary drug delivery system proneura™, which is capable of delivering sustained, consistent levels of medication for up to 12 months. the proneura technology has the potential to be used in developing products for treating other chronic conditions such as parkinson's disease and hypothyroidism, where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes.

Complete history of David Investing stock trades at Titan Pharmaceuticals, (de)

Titan Pharmaceuticals, (de) executives and stock owners

Titan Pharmaceuticals, (de) executives and other stock owners filed with the SEC include:

• Marc Rubin,
  Executive Chairman of the Board, Chief Executive Officer
• Katherine DeVarney,
  President, Chief Operating Officer, Chief Scientific Officer, Director
• Dr. Katherine L. Beebe-DeVarney Ph.D.,
  Pres, COO & Director
• Dr. Marc Rubin M.D.,
  Exec. Chairman & Principal Exec. Officer
• Stephen Kilmer,
  Investor Relations
• James McNab,
  Independent Director
• M. David MacFarlane,
  Independent Director
• Joseph Akers,
  Independent Director
• Scott Smith,
  Independent Director
• Joe Schrei,
  Exec. Director of Commercial Operations
• Jennifer Kiernan,
  Exec. Assistant to CEO & Investor Communications Coordinator
• Mike Fritz,
  National Sales Director
• Brian E. Crowley,
  VP of Fin.
• Dane Hallberg,
  See Remarks
• Eurelio M Cavalier,
  Director
• Sunil Bhonsle,
  President and CEO
• Choon Hau Choong,
  10% owner
• Rajinder Kumar,
  Director
• Matthew Charles Mc Murdo,
  Director
• David Natan,
  Director
• Peter Louis Chasey,
  Director
• Federico Seghi Recli,
  Director
• Avraham Ben Tzvi,
  Director
• David E. Lazar,
  Chief Executive Officer
• Eric Howard Greenberg,
  Director
• Katherine Beebe,
  President and COO
• David E.Activist Investing ...,
  Chief Executive Officer